Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

54.35 +5.81 (+11.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Moderna (MRNA) Shares Skyrocket, What You Need To Know
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 10.2% in the afternoon session after the company published positive Phase 3 clini... 
Via StockStory
Topics Intellectual Property
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
These S&P500 stocks have an unusual volume in today's session ↗
Via Chartmill
Which S&P500 stocks are moving on Friday? ↗
Via Chartmill
News headline image
Moderna Stock Rises On Positive Phase 3 Flu Data: What Investors Need To Know ↗
Moderna Inc (NASDAQ: MRNA) shares are trading higher Friday morning as traders react to peer reviewed Phase 3 flu-vaccine data. 
Via Benzinga
Moderna Inc (NASDAQ:MRNA) Surges Past Q1 Estimates on International Strength ↗
Via Chartmill
News headline image
5 Insightful Analyst Questions From Moderna’s Q1 Earnings Call
Moderna’s first quarter was marked by a sharp increase in revenue, driven by the fulfillment of large international contracts, particularly through a strateg... 
Via StockStory
Topics Earnings Intellectual Property
News headline image
Moderna Stock Gives Back Early Gains: What's Happening? ↗
Moderna, Inc. (NASDAQ:MRNA) shares initially surged Thursday, but have since retreated after the company announced the publication of its Phase 3 study results evaluating mRNA -1010 in the New England... 
Via Benzinga
Top S&P500 movers in Thursday's pre-market session ↗
Via Chartmill
News headline image
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
Via ACCESS Newswire
These S&P500 stocks are moving in today's session ↗
Via Chartmill
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
MRNA Q1 Deep Dive: International Partnerships and Pipeline Progress Offset Litigation Headwinds
Biotechnology company Moderna (NASDAQ:MRNA) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 260% year on year to $389 mil... 
Via StockStory
These S&P500 stocks are moving in today's session ↗
Via Chartmill
News headline image
Moderna (MRNA) Q1 2026 Earnings Transcript ↗
Moderna (MRNA) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Moderna (NASDAQ:MRNA) Beats Expectations in Strong Q1 CY2026, Stock Soars
Biotechnology company Moderna (NASDAQ:MRNA) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 260% year on year to $389 mi... 
Via StockStory
What's going on in today's pre-market session: S&P500 movers ↗
Via Chartmill
News headline image
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates
Via ACCESS Newswire
News headline image
Moderna (MRNA) Reports Earnings Tomorrow: What To Expect
Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Friday morning. Here’s what you need to know. Moderna beat analysts’ revenue expec... 
Via StockStory
These S&P500 stocks are gapping in today's session ↗
Via Chartmill
News headline image
3 Healthcare Stocks With the Most Durable Competitive Moats ↗
These companies offer a clear path to sustained earnings growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
Via ACCESS Newswire
News headline image
Got $2,000? These Biotech Stocks Are Worth Considering for Long-Term Growth ↗
It will be a turbulent ride, but patient investors might come out of it much richer. 
Via The Motley Fool
News headline image
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
Via ACCESS Newswire
News headline image
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
Via ACCESS Newswire
News headline image
Moderna to Present at Upcoming Conferences in May 2026
Via ACCESS Newswire
News headline image
What's Pushing Moderna Stock Higher Today? ↗
Moderna (NASDAQ:MRNA) shares are moving higher on Monday after the company won FDA Fast Track status for an oncology program. 
Via Benzinga
News headline image
Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting
Via ACCESS Newswire
News headline image
Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
Via ACCESS Newswire
News headline image
3 Unpopular Stocks We Approach with Caution
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.